Johnson & Johnson Reports Encouraging Late-Stage Results for Novel Head and Neck Cancer Therapy
OrigAMI-4 study shows strong tumor responses in patients with recurrent or metastatic head and neck cancer after standard treatments fail. Johnson & Johnson has announced promising clinical results for its investigational therapy RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in patients with advanced head and neck squamous cell carcinoma (HNSCC), a disease where treatment options remain limited once standard therapies stop working.












